Ingrid E Graves

Ms. Ingrid E Graves

In Vivo Pharmacology & Macro-Molecular Discovery, Arbutus Biopharma, Warminster, Pennsylvania, USA
+2
orcid

Research Focus & Metrics

Academic Career Length

20Years (2007-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2010 in Journal of Cancer
Verified
Journal Article
Open access
IGIngrid E Graves
Ingrid E Graves
JMJeffrey T. Mason
Jeffrey T. Mason
TOTIMOTHY OLEARY
TIMOTHY OLEARY
CFCarol B. Fowler
Carol B. Fowler
Formaldehyde fixation and paraffin-embedding remains the most widely used technique for processing cancer tissue specimens for pathologic examination, the study of tissue morphology, and archival preservation. However, formaldehyde penetration and fixation is a slow process, requiring a minimum of 15 hr for routine processing of pathology samples. Routinely fixed samples often have a well-fixed outer rim, with a poorly-fixed inner core of tissue. In this study, we show that the application of elevated pressure up to 15,000 psi improves the rate of formaldehyde fixation by approximately 5 to 7-fold while preserving the tissue morphology of porcine liver. The tissue also exhibited much more uniform formaldehyde penetration after 30-60 min incubation under elevated pressure than samples fixed for the same length of time at atmospheric pressure.

8 December 2010 in PLOS ONE
Verified
Journal Article
Open access
PDF file
CFCarol B. Fowler
Carol B. Fowler
IGIngrid E Graves
Ingrid E Graves
CMCedric D. Moore
Cedric D. Moore
TOTIMOTHY OLEARY
TIMOTHY OLEARY
JMJeffrey T. Mason
Jeffrey T. Mason
Proteomic studies of formalin-fixed paraffin-embedded (FFPE) tissues are frustrated by the inability to extract proteins from archival tissue in a form suitable for analysis by 2-D gel electrophoresis or mass spectrometry. This inability arises from the difficulty of reversing formaldehyde-induced protein adducts and cross-links within FFPE tissues. We previously reported the use of elevated hydrostatic pressure as a method for efficient protein recovery from a hen egg-white lysozyme tissue surrogate, a model system developed to study formalin fixation and histochemical processing. In this study, we demonstrate the utility of elevated hydrostatic pressure as a method for efficient protein recovery from FFPE mouse liver tissue and a complex multi-protein FFPE tissue surrogate comprised of hen egg-white lysozyme, bovine carbonic anhydrase, bovine ribonuclease A, bovine serum albumin, and equine myoglobin (55∶15∶15∶10∶5 wt%). Mass spectrometry of the FFPE tissue surrogates retrieved under elevated pressure showed that both the low and high-abundance proteins were identified with sequence coverage comparable to that of the surrogate mixture prior to formaldehyde treatment. In contrast, non-pressure-extracted tissue surrogate samples yielded few positive and many false peptide identifications. Studies with soluble formalin-treated bovine ribonuclease A demonstrated that pressure modestly inhibited the rate of reversal (hydrolysis) of formaldehyde-induced protein cross-links. Dynamic light scattering studies suggest that elevated hydrostatic pressure and heat facilitate the recovery of proteins free of formaldehyde adducts and cross-links by promoting protein unfolding and hydration with a concomitant reduction in the average size of the protein aggregates. These studies demonstrate that elevated hydrostatic pressure treatment is a promising approach for improving the recovery of proteins from FFPE tissues in a form suitable for proteomic analysis.

22 September 2024 in ACS Infectious Diseases
Verified
Journal Article
Closed access
ETEmily P. Thi
Emily P. Thi
XYXin Ye
Xin Ye
NSNicholas M. Snead
Nicholas M. Snead
ALAmy C. H. Lee
Amy C. H. Lee
HSHolly M. Micolochick Steuer
Holly M. Micolochick Steuer
MSMichael J. Sofia
Michael J. Sofia

31 December 2020 in Molecular Carcinogenesis
Verified
Journal Article
Closed access
PDF file
PPPornima Phatak
Pornima Phatak
MNMichael Noe
Michael Noe
KAKaushal Asrani
Kaushal Asrani
IGIngrid E Graves
Ingrid E Graves
BGBruce D. Greenwald
Bruce D. Greenwald
JDJames M Donahue
James M Donahue

4 September 2024 in Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
ACAndrew G. Cole
Andrew G. Cole
SKSteven G. Kultgen
Steven G. Kultgen
NMNagraj Mani
Nagraj Mani
KFKristi Yi Fan
Kristi Yi Fan
AAAndrzej Ardzinski
Andrzej Ardzinski
MSMichael J. Sofia
Michael J. Sofia

21 February 2024 in Viruses
Verified
Journal Article
Open access
PDF file
ALAngela M Lam
Angela M Lam
RDRavi R Dugyala
Ravi R Dugyala
MSMuhammed Sheraz
Muhammed Sheraz
FLFei Liu
Fei Liu
ETEmily P. Thi
Emily P. Thi
ASAnd Michael J Sofia
And Michael J Sofia
HBV RNA destabilizers are a class of small-molecule compounds that target the noncanonical poly(A) RNA polymerases PAPD5 and PAPD7, resulting in HBV RNA degradation and the suppression of viral proteins including the hepatitis B surface antigen (HBsAg). AB-161 is a next-generation HBV RNA destabilizer with potent antiviral activity, inhibiting HBsAg expressed from cccDNA and integrated HBV DNA in HBV cell-based models. AB-161 exhibits broad HBV genotype coverage, maintains activity against variants resistant to nucleoside analogs, and shows additive effects on HBV replication when combined with other classes of HBV inhibitors. In AAV-HBV-transduced mice, the dose-dependent reduction of HBsAg correlated with concentrations of AB-161 in the liver reaching above its effective concentration mediating 90% inhibition (EC90), compared to concentrations in plasma which were substantially below its EC90, indicating that high liver exposure drives antiviral activities. In preclinical 13-week safety studies, minor non-adverse delays in sensory nerve conductance velocity were noted in the high-dose groups in rats and dogs. However, all nerve conduction metrics remained within physiologically normal ranges, with no neurobehavioral or histopathological findings. Despite the improved neurotoxicity profile, microscopic findings associated with male reproductive toxicity were detected in dogs, which subsequently led to the discontinuation of AB-161’s clinical development.